Real-World Evidence (RWE) & Post-Market Surveillance:
25. Real-World Evidence (RWE) & Post-Market Surveillance:
In the Pharma 2024 Conference session, we explore the growing importance of real-world evidence (data collected outside of traditional clinical trials) in evaluating drug safety and effectiveness in real-world settings. It also covers the role of post-market surveillance in identifying and mitigating risks associated with marketed drugs.
25-1 RWE study design and methodology
25-2 Integrating RWE with clinical trial data
25-3 Post-market safety monitoring and pharmacovigilanc
25-4 RWE in regulatory decision-making